BFM
INTS icon

Boothbay Fund Management’s Intensity Therapeutics INTS Stock Holding History

Boothbay Fund Management’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-600
Closed -$4.61K – 2010
2025
Q2 		$4.61K Buy
+600
New +$12.3K ﹤0.01% 1412

Other funds holding INTS

SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
SFGP
Stonebridge Financial Group (Pennsylvania) Wormleysburg, Pennsylvania $1.32B AUM 23.07% 1-Year Est. Return

Boothbay Fund Management's INTS Position: Q3 2025 in Review

Boothbay Fund Management sold out of Intensity Therapeutics (INTS) in Q3 2025, closing a stake of 600 shares — an estimated $4.61K sold.

Boothbay Fund Management first reported a position in INTS in Q2 2025 and held it in 1 quarter. The position peaked at $4.61K in Q2 2025. 26 funds tracked by Wall St. Rank hold INTS as of Q3 2025.

  • Boothbay Fund Management reported no remaining Intensity Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 600 Intensity Therapeutics shares in Q3 2025, an estimated $4.61K.
  • Boothbay Fund Management first reported a position in Intensity Therapeutics in Q2 2025 and held it in 1 quarter.
  • Boothbay Fund Management's Intensity Therapeutics position peaked at $4.61K in Q2 2025.
  • 26 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q3 2025.

Based on Boothbay Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.